Famciclovir exhibits a broad spectrum of bioactivities across various in vitro and in vivo studies. It demonstrates significant antiviral activity against herpes simplex virus type 1 (HSV-1) with an EC50 value greater than 100,000.0 nM and shows cytotoxicity in Vero cells with a CC50 over 500,000.0 nM. Additionally, it has been observed to exhibit antiviral activity against viruses such as BK polyomavirus, woodchuck hepatitis virus, and SARS-CoV-2, although its efficacy against SARS-CoV-2 appears relatively low with inhibition rates and EC50 values indicating moderate potency.
In pharmacokinetic studies, Famciclovir shows high oral bioavailability at 77.0% in humans, moderate oral clearance, and a relatively short half-life, accompanied by high systemic exposure and quick absorption. It demonstrates significant urinary recovery of penciclovir in both mice (48.0%) and rats (40.0%) over a 48-hour period post-administration.
The compound also exhibits inhibitory activity against several biological targets including HSD17B4, JMJD2E, Cruzain, ALDH1A1, HPGD, and the Relaxin Receptor RXFP1, and shows potency in inhibiting the proliferation of Plasmodium falciparum strains. It inhibits sodium fluorescein uptake in OATP1B1 and OATP1B3-transfected cells significantly, with inhibition percentages of 68.22% and 68.05%, respectively.
However, Famciclovir has been associated with certain levels of hepatotoxicity indicated by the increase in liver enzymes such as ALT, AST, and alkaline phosphatase. The HepSE score for bilirubinemia and other liver function abnormalities suggests potential liver injury risks. Additional bioassays reveal varying effects on other biomarkers, indicating a notable impact on liver, kidney, blood, and metabolic functions.
Overall, Famciclovir exhibits a complex profile with significant antiviral and antiprotozoal activities, moderate potency in inhibition assays, and notable pharmacokinetic properties, combined with a potential risk for liver toxicity. Further investigation and careful assessment are warranted to fully understand its therapeutic potential and safety profile..
Note: Summary generated by AI. Data source: ChEMBL 